Jubilant Draximage Recalls DRAXIMAGE DTPA Kits Due to Stability Failures
Jubilant Draximage is recalling DRAXIMAGE DTPA kits because they failed stability specifications. The affected product was distributed throughout the United States.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: The recall is classified as FDA Class II, and the source text does not report any illnesses, injuries, or hospitalizations, fitting the criteria for a moderate severity rating.
Plain-English summary
Jubilant Draximage, Inc. is recalling DRAXIMAGE DTPA (Kit for the Preparation of Technetium Tc 99m Pentetate Injection), 20 mg vial, Rx only. The recall is being conducted because the product failed stability specifications. The affected product is identified by Lot # 8K143 with an expiration date of 10/31/2020.
The recall involves 473 kits of 30 vials. The product was distributed throughout the United States. The NDC numbers for the affected product are 65174-288-05 and 67175-288-30.
Healthcare providers and patients should stop using the affected product and contact Jubilant Draximage, Inc. for further instructions. This recall is classified as Class II by the FDA.
The recalled product
- Product
- DRAXIMAGE DTPA (KIT FOR THE PREPARATION OF TECHNETIUM TC 99M PENTETATE INJECTION), 20 mg vial, Rx only, Manufactured for: Jubilant Draximage, Inc., Kirkland, Quebec, Canada, NDC 65174-288-05, 67175-288-30
- Manufacturer
- Jubilant Draximage Inc
- Category
- Drug — Radiopharmaceutical
- Hazard
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot # 8K143
- Exp 10/31/2020.
Distribution
Distribution scope not specified by the agency.
Related recalls
Same manufacturer · Jubilant Draximage Inc
See all →- HighDrug Recall: Draximage MAA Injectable Kit Due to Sterility Failure
FDA (Drugs) · 2022-07-20
- LowJubilant DraxImage Recalls Sodium Iodide I 131 Diagnostic Due to Labeling Error
FDA (Drugs) · 2016-04-13
Same hazard · stability failure
See all →- ModerateApotex Recalls Paxil Tablets for Failed Dissolution and Stability Testing
FDA (Drugs) · 2026-09-02
- ModerateVasocaine lidocaine spray recalled because stability data does not support expiry
FDA (Drugs) · 2026-03-11
- ModerateZone 1 lidocaine cream recalled because stability data does not support expiry
FDA (Drugs) · 2026-03-11
- ModerateZone 2 lidocaine cream recalled because stability data does not support expiry
FDA (Drugs) · 2026-03-11
- ModerateCiclopirox shampoo recalled after failing impurity specifications at eighteen months
FDA (Drugs) · 2025-12-24